Download lesson plan with multimedia

Kelly Walters
[email protected]
N6803 Tice Road
Winter, WI 54896
(715)266-5247
EDUCATION
2015-present
Drexel University
Master’s in teaching, learning, and curriculum. Secondary education, General science.
Expected December 2016
1996-2001
DePaul University
Bachelor of Science, Major in Chemistry (Biochemistry Focus)/Minor in Computer Science,
awarded June 17, 2001
WORK EXPERIENCE
8/2013-8/2014
CPC Pathology
Molecular Technologist
Philip Murray, Ph.D. Consolidated Pathology Consultants. Libertyville, IL.
Solely managed and maintained entire molecular department for CLIA and CAP certified
pathology laboratory. Prepare and perform Laser Scanning Cytometry, and FISH on clinical
patient samples. Assisted IT when necessary for orchard software troubleshooting.
Responsibilities:
 Performed FISH on blood, bone marrow, and tissue (hematological panels)
(approximately 90 cases annually).
 Performed laser scanning cytometry on blood, bone marrow, tissue, and other body
fluids (approximately 800 cases annually).
 Received administrator training for orchard software.
 Handled send out cases for additional molecular testing not provided by our
laboratory.
 Resulted blood work and assisted with appropriate ICD-9 coding for billing
purposes.
 Participated in proficiency testing for CAP.
2010-Nov. 2013
RUSH
Research Assistant
Lela Buckingham, Ph.D. Rush University Medical Center Department of Pathology/Molecular
Oncology Chicago,IL. Determine the influence of amplification or deletion of novel genes on
tumor progression. In addition we work on studies related to novel targeted chemotherapy
drugs such as, Avastin, Alimta, and Tarceva. In conjunction with some of these studies we have
been focused on Epithelial-Mesenchymal transition (EMT). Work on Epigenetic related
changes in cancer and their prognostic significance. Research spans the areas of Lung, Breast,
Colon, and Ovarian malignancies.
Responsibilities:
 Establishing and maintaining an on-line clinical data repository (Ciasis)
 Trained in reading FISH (interphase) slides (break apart probes, single probes, and
probe mixes) and processing. (Vysis/Abbott, Des Plaines, IL)
 Perform immunohistochemistry (Benchmark, Benchmark XT, Leica, and DAKO
Automated staining systems), and other special stains.
 DNA sequencing, pyrosequencing, methylite, and various PCR methods.
 Use and Maintain Microtome for both frozen and Paraffin embedded samples.
 Create and maintain clinical databases related to studies.
2001-2010
RUSH
Research Assistant
Dr. John S. Coon, M.D., Ph.D. Rush University Medical Center Department of Pathology.
Chicago, IL. Focus on determining prognostic markers that can predict outcome and/or
response to chemotherapy. Determine the influence of amplification or deletion of novel genes
on tumor progression. In addition we work on studies related to targeted chemotherapy drugs
such as Iressa, Herceptin, and Tarceva. Research spans the areas of Lung, Breast, Colon, Oral
Cavity, Ovarian, and Hematological malignancies.
Responsibilities:
 Trained in reading FISH (interphase) slides and processing. (Vysis/Abbott, Des
Plaines, IL)
 Perform immunohistochemistry (Benchmark, Benchmark XT, Leica, and DAKO
Automated staining systems), and other special stains.
 Study Coordinator for Lung Repository and Oncology Lung repository
 Snap freeze and paraffin embed specimen.
 Process Serum and Plasma Blood specimen for proteomic analysis.
 DNA sequencing, pyrosequencing, and various PCR methods.
 Use and Maintain Microtome for both frozen and Paraffin embedded samples.
 Created and maintained clinical databases related to studies.
 Manage research lab and employees.
2008-2010
Histotechnologist, Selma George, Rush University Medical Center, Department of Pathology.
Chicago, IL. Worked part-time in a CAP and CLIA certified clinical pathology lab.
Responsibilities:


1/07-04/07
Histology Laboratory processing and embedding of Formalin Fixed Tissue.
Distributed Hematoxylin and Eosin stained cases to attending pathologists for review
and Sign-out.
Immunohistologist, Kathy Clodfelter, Rush University Medical Center, Department of
Pathology. Chicago, IL. Worked part-time in the clinical pathology lab (CAP and CLIA) (while
short staffed) performing immunohistochemistry.
Responsibilities:


2003
2/8/03-3/15/03
3/2004
2000-2001
Cut formalin fixed paraffin embedded tissue.
Prepared tissue for automated staining using the DAKO autostainer, Ventana
Benchmark, and Nexes ES systems.
Oceanographic Scientist
Joseph P. Resing, Ph.D., Joint institute for study of Atmosphere and Ocean. Surveyed the
Mariana arc submarine volcanoes using side scan sonar and hydrocasting to identify distribution
of hydrothermal activity and its relationship to the geophysical properties of the individual
volcanoes.
Responsibilities:
 Analyzed deepwater fluids by sampling water for pH and trace metals (Fe and Mn).
 Estimated the CO2 levels from our pH measurements (were calculated based on the
ocean carbonate system).
Physical Chemistry Teaching Assistantship, DePaul University, Laboratory TA. Chicago, IL.
Headed the laboratory section of the course, Lab setup, and chemical preparation.
Responsibilities:
 Taught students in their chemistry laboratory
 Tutored students in their chemistry lab and lecture courses
 Evaluated student lab reports
2000-2001
DePaul University Women’s Soccer, DePaul University, Assistant Coach
Assisted the head Coach of the NCAA Division I Women’s Soccer program.
Responsibilities:
 Coordinated Team travel plans and competitive schedule
 Instructed goalkeepers in games and practice
 Traveled to recruit potential players
1999-2001
Near North Insurance Brokerage, Accountants Assistant. Chicago, IL.
Was the assistant to the personal accountant for the owners of Near North Insurance Brokerage.
 Managed computer/database related tasks
 Maintained personal finances and accounts for the owners of the Company.
P UBLICATIONS
1.
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell
lung cancer. Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi
P. Anticancer Res. 2012 May; 32(5):1705-10.
2.
PKCalpha and ERbeta are Associated with Triple-Negative Breast Cancers in African-American and
Caucasian Patients. Debra A. Tonetti, Weihua Gao, Diana Escarzaga, Kelly Walters, April Szafran and
John Coon. International Journal of Breast Cancer, vol. 2012, Article ID 740353, 9 pages, 2012.
doi:10.1155/2012/740353
3.
Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell
lung cancer with circulating autoantibody biomarkers. Kalpa Patel, Erin C. Farlow, Anthony W. Kim, BaoShiang Lee, Sanjib Basu, John S. Coon, David DeCresce, Lida Timothy, Kelly A. Walters, Cristina Fhied,
Christopher chang, Ssu-Hsien Chen, L Panfield Faber, Philip Bonomi, Michael J Liptay, Jeffrey A Borgia.
International Journal of Cancer. Volume 129, Issue 1, pages 133–142, 1 July 2011
4.
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with
gefitinib therapy. M J Fidler, L E Morrison, S Basu, L Buckingham, K Walters, M Batus, K K Jacobson, S
S Jewell, J Coon IVand P D Bonomi. British Journal of Cancer (2011) 105, 1920–1926.
5.
PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II
nonsmall cell lung cancer patients. Lela Buckingham, L. Penfield Faber, Anthony Kim, Michael Liptay,
Carter Barger, Sanjib Basu, Mary Fidler, Kelly Walters, Philip Bonomi, John Coon. Volume 126, Issue 7,
pages 1630–1639, 1 April 2010.
6.
Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small
cell lung cancer. Borgia JA, Basu S, Faber LP, Kim AW, Coon JS, Kaiser-Walters KA, Fhied C, Thomas S,
Rouhi O, Warren WH, Bonomi P, Liptay MJ. J Thorac Oncol. 2009 Mar; 4(3):338-47.
7.
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal
Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Mary J. Fidler, Athanassios Argiris, Jyoti D. Patel, David H. Johnson, Alan Sandler, Victoria M. Villaflor,
John Coon, IV, Lela Buckingham, Kelly Kaiser, Sanjib Basu and Philip Bonomi Clinical Cancer Research
14, 2088-2094, April 1, 2008
8.
The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with
Gefitinib Buckingham, Lela E. PhD; Coon, John S. MD, PhD; Morrison, Larry E. PhD; Jacobson, Kristine
K. B. MSc; Jewell, Susan S. PhD; Kaiser, Kelly A. BSc ; Mauer, Ann M. MD; Muzzafar, Tariq MD;
Polowy, Clayton MD; Basu, Sanjib PhD; Gale, Meryl MSc; Villaflor, Victoria M. MD; Bonomi, Philip
MD. Journal of Thoracic Oncology. 2(5):414-422, May 2007
ABSTRACTS
1.
IHC versus FISH for the detection of ERG rearrangements in prostate cancer. Ekaterina Pestova, Ying
Zhang, William Barbanera, Kelly A. Kaiser-Walters, Jing Du, Ping Liu, Lela Buckingham, Tracey Colpitts.
J Clin Oncol 33, 2015 (suppl 7; abstr 102)
2.
Biomarkers of phenotypic plasticity associate with clinical outcomes in patients with locally-advanced
NSCLC treated with chemoradiotherapy with and without surgery. Marta Batus, MD; Mary J Fidler, MD;
Mark Pool, MD, Sanjib Basu, PhD, Kelly A. Kaiser-Walters, BS; Shruthi Melinamani, MD; Brett Mahon,
MD; Jeffrey A. Borgia, PhD; and Philip Bonomi, MD. Journal of Thoracic Oncology, WCLC 2013
abstracts. Vol 8, Suppl 2, November 2013: S500 (P1.06-052).
3.
Circulating biomarkers may help guide selection of erlotinib versus chemotherapy in pretreated advanced
NSCLC patients. Jeffrey A. Borgia, PhD; Mary J Fidler, MD, Anjali Gangaram, MD, Sanjib Basu, PhD,
Cristina Fhied, Kelly A. Kaiser-Walters, BS, Brett Mahon, MD, and Philip Bonomi, MD. Journal of
Thoracic Oncology, WCLC 2013 abstracts. Vol 8, Suppl 2, November 2013: S1097 (P3.06-051).
4.
Genetic Aberations in PTEN and PIK3CA and prognosis in wild-type EGFR gene mutation in patients that
received erlotinib. Mary J. Fidler, Ekaterina Pestova, Ying Zhang, Jing Du, Philip D. Bonomi, Thomas A.
Hensing, Kelly Kaiser Walters, William Barbanera, Lela Buckingham. J Clin Oncol 32, 2014 (suppl; abstr
e22043).
5.
Epithelial to mesenchymal markers and clinical outcomes on erlotinib in stage IV non-small cell lung
cancer patients. Mark Pool, Mary J. Fidler, Sanjib Basu, Brett Mahon, Lela Buckingham, Kelly Kaiser
Walters, Marta Batus, Thomas A. Hensing, Jeffrey A Borgia and Philip D. Bonomi. Journal of Clinical
Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 31, No 15_suppl (May
20 Supplement), 2013: e19117.
6.
Thyroid transcription factor 1 (TTF-1) and overall survival in wild type EGFR patients treated with
erlotinib. Mary J. Fidler, Sanjib Basu, Thomas A. Hensing, Lela Buckingham, Mark Pool, Brett Mahon,
Marta Batus, Kelly Kaiser Walters and Philip D. Bonomi. Journal of Clinical Oncology, 2013 ASCO
Annual Meeting Proceedings (Post-Meeting Edition). Vol 31, No 15_suppl (May 20 Supplement), 2013:
e19113.
7.
Correlation of OGlcNAc modification components and EMT/Stem cell markers in lung adenocarcinoma.
Rouhi O, Arvanitis L, Kaiser K, Marconi P, Sanjib B, Mahon B, Pool M, Usha L, Liptay M, Bonomi P,
Borgia JA. American Association of Cancer Research. Cancer Res 2012;72(8 Suppl):Abstract nr 2404
8.
Prognostic value of OGlcNAc modification and its related enzymes in lung adenocarcinoma. Rouhi O,
Arvanitis L, Kaiser K, Sanjib B, Mahon B, Pool M, Liptay M, Bonomi P, Borgia J.A. United States and
Canadian Academy of Pathology (USCAP); British Columbia, Canada. March, 2012.
9.
Expression of EMT-Stem cell like biomarkers in lung adenocarcinoma isotypes. Rouhi O, Kaiser K, Sanjib
B, Pool M, Mahon B, Liptay M, Bonomi P, Borgia JA. USCAP; British Columbia, Canada. March, 2012.
10. Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC)
patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival
(OS). Marta Batus, Mary J. Fidler, Kelly Kaiser Walters, Mark Pool, Brett Mahon, Sanjib Basu, Jeffrey
Allen Borgia, David Sher and Philip D. Bonomi. Journal of Clinical Oncology, 2012 ASCO Annual
Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20 Supplement), 2012: 7067.
11. Panel of serum biomarkers to predict benefit from bevacizumab (BEV) in advanced NSCLC patients.
Eduardo Braun, Mary J. Fidler, Sanjib Basu, Anjali Gangaram, Kelly Kaiser Walters, Reem Karmali,
Cristina Fhied, Wen-rong Lie, Jeffrey Allen Borgia and Philip D. Bonomi. Journal of Clinical Oncology,
2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20
Supplement), 2012: e21069.
12. EGFR gene mutation and epithelial to mensenchymal transition (EMT) markers in advanced NSCLC
patients treated with erlotinib. Mary J. Fidler, Manish J Dave, Sanjib Basu, Thomas A. Hensing, Mark
Pool, Brett Mahon, Jeffrey A Borgia, Kelly Kaiser Walters, Diana Escarzaga, Marta Batus and Philip D.
Bonomi. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 30, No 15_suppl (May 20 Supplement), 2012: e18117.
13. Histologic subtyping and tumor stromal responses in advanced-stage lung adenocarcinoma and their
relationship to survival. M. D. Pool, M. J. Fidler, K. A. Kaiser-Walters, S. Basu, E. Braun, L. Buckingham,
T. A. Hensing and P. D. Bonomi. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings
(Post-Meeting Edition). Vol 29, No 15_suppl (May 20 Supplement), 2011: e21135.
14. Increased Bcl-2 expression is associated with Bax promoter hypermethylation in neuroendocrine carcinoma
(NEC) of the lung. D. C. McFarland, M. Batus, L. Buckingham, J. Coon, S. Basu, M. J. Fidler, K. K.
Walters, J. A. Borgia and P. D. Bonomi. Journal of Clinical Oncology, 2011 ASCO Annual Meeting
Proceedings (Post-Meeting Edition). Vol 29, No 15_suppl (May 20 Supplement), 2011: e21136.
15. Serum protein levels may be useful in selecting treatment with an epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR TKI) versus chemotherapy in previously treated non-small cell lung cancer
(NSCLC) patients. Mary Jo Fidler, Reem Karmali, Marta Batus, Sanjib Basu, Brett Mahon, Omid Rouhi,
Cristina Fhied, David D. Shersher, Kelly A. Walters, Philip Bonomi, and Jeffrey A. Borgia. 14th World
Congress on Lung Cancer. July 3-7th, 2011 Amsterdam, the Netherlands. Abstract 2999
16. Serum Biomarkers for Apoptosis for prognosticating progression-free and overall outcomes in advanced
non-small cell lung cancer (NSCLC). Jeffrey A. Borgia, Reem Karmali, Mary Jo Fidler, Sanjib Basu, Brett
Mahon, Omid Rouhi, David D. Shersher, Cristina Fhied, Kelly A. Kaiser, Marta Batus, and Philip Bonomi.
14th World Congress on Lung Cancer. July 3-7th, 2011. Amsterdam, the Netherlands. Abstract 2561
17. Serum Biomarkers for Angiogenesis have value for prognosticating progression-free and overall outcomes
in advanced NSCLC. Reem Karmali, Mary Jo Fidler, Marta Batus, Sanjib Basu, Brett Mahon, Omid Rouhi,
Cristina Fhied, Gabriela Lobato, Kelly A. Walters, Philip Bonomi and Jeffrey A. Borgia. 14th World
Congress on Lung Cancer. July 3-7th, 2011. Amsterdam, the Netherlands. Abstract 3004.
18. Comparing stem cell markers expression between primary and metastatic lymph node tumors of NSCLC.
Rouhi O, Gallegos M, Kaiser-Walters K.A, Escarzaga D, Steker D, Basu S, Liptay M.J, Gattuso P, Bonomi
P, Coon J, Borgia J.A. (2010, September) Poster presented at: AACR (Metastasis and the Tumor
Microenvironment); Philadelphia, PA.
19. Evaluation of epithelial-to-mesenchymal transition markers and CXCR4 in primary and metastatic lymph
node tumors of NSCLC. Rouhi O, Marconi P, Gallegos M, Kaiser-Walters K.A, Escarzaga D, Steker D,
Basu S, Liptay M.J, Gattuso P, Bonomi P, Coon J, Borgia J.A. (2010, September) Poster presented at:
AACR (Metastasis and the Tumor Microenvironment); Philadelphia, PA.
20. Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival
(OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy. R. Karmali, M.
J. Fidler, I. Cela, G. Olmsted, O. Rouhi, S. Basu, K. K. Walters, J. Coon, P. Bonomi and J. A. Borgia.
Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28,
No 15_suppl (May 20 Supplement), 2010: 7553.
21. Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced nonsmall cell lung cancer (NSCLC) patients treated with erlotinib. N. B. Shah, M. J. Fidler, K. K. Walters, E.
Braun, S. Basu, H. Harasty, J. Coon, M. Pool, T. A. Hensing, P. D. Bonomi. Journal of Clincal Oncology,
2010 ASCO Annual Meerting Proceedings (Post-meeting edition) Vol 28, No 15_suppl (May 20
Supplement), 2010: 7550.
22. Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with
neoadjuvant chemoradiation. M.J. Fidler, S. Basu, K.A. Kasier-Walters, E. Hadziahmetovic, M.Batus, D.
Steker, J. Coon, P. Bonomi. Journal of Clincal Oncology, 2010 ASCO Annual Meerting Proceedings (Postmeeting edition) Vol 28, No 15_suppl (May 20 Supplement), 2010: 7034.
23. Mcl-1 and bcl-2 expression in neuroendocrine carcinoma (NEC) and potential for new therapeutic target.
M. Batus, D. C. McFarland, J. Coon, S. Basu, M. Pool, R. Myint, K. K. Walters, M. J. Fidler and P. D.
Bonomi. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 28, No 15_suppl (May 20 Supplement), 2010: e21039.
24. The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung
cancer (NSCLC) treated with erlotinib. T. A. Hensing, M. J. Fidler, F. Wong, A. Polish, W. Watkin, S.
Basu, K. A. Kaiser-Walters, M. Pool, J. Coon and P. Bonomi. Journal of Clinical Oncology, 2010 ASCO
Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010:
7552.
25. Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer. O. Rouhi, K. A.
Kaiser-Walters, D. Escarzaga, D. Steker, S. Basu, M. J. Liptay, P. Gattuso, P. D. Bonomi, J. Coon and J. A.
Borgia. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 28, No 15_suppl (May 20 Supplement), 2010: 7620.
26. Serum Screening Test for Non-Small cell lung cancer. E.C.Farlow. A.W. Kim, S, Basu, S. Panicker, C.
Fhied, O. Rouhi, K.A. Kaiser, L.P. Faber, W.H. Warren, P. Bonomi, J.S. Coon, J.A. Borgia. Journal of
Surgical Research. Volume 151, Issue 2, Page 174, February 2009.
27. Tumor survivin expression in locally advanced non-small cell lung cancer (NSCLC) patients treated with
platinum-based chemoradiation followed by surgical resection. M. J. Fidler, A. Seba, E. C. Farlow, S.
Basu, K. Kaiser-Walters, D. Steker, J. Coon, IV, A. W. Kim, P. Bonomi and L. P. Faber. Journal of
Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S
(May 20 Supplement), 2009: 7595.
28. N-Cadherin, E-Cadherin, ERCC1 nad c-kit expression in small cell lung cancer (SCLC) and potential for
new therapeutic changes. M. Batus, R. Myint, J. Coon, S. Basu, K. Kaiser, M.Fidler and P Bonomi. Journal
of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 27, No 15S
(May 20 Supplement), 2009:e22157.
29. Insulin-like growth factor binding proteins and response in advanced non-small cell lung cancer (NSCLC)
patients treated with erlotinib. M.J. Fidler, A. Gimelfarb, I. Dehghan-Paz, S. Basu, C. Fhied, K.A. KaiserWalters, E.C. Farlow, O. Rouhi, M. Batus, J.S. Coon, P. Bonomi, J.A. Borgia. The 13th World Conference
on Lung Cancer. San Francisco, CA, July 31-August 4th, 2009.
30. Immunohistochemistry of biomarkers associated with metastatic and cancer stem cell-like phenotypes in
non-small cell lung cancer. Omid Rouhi, Kelly A Kaiser-Walters, Diana Escarzaga, Danielle Steker, Sanjib
Basu, Anthony W. Kim, Michael J. Liptay, L. Penfield Faber, Philip Bonomi, John S. Coon, Jeffrey A.
Borgia. The 13th World Conference on Lung Cancer. San Francisco, CA, July 31-August 4th, 2009.
31. Expression of activated Akt (And two other related Proteins) in unresectable NSCLC does not correlate
with radiologic chemoresponse. S Pasha, SZ Ahmed, PS Talwar, ML Hearp, K Kaiser, JS Coon, O David.
Modern Pathology, Jan 2008; 21 (Supplement 1s): 334A-353A [1562].
32. Frequency of Insulin-like growth factor 1(IGF-R1) expression and correlation with clinical and selected
molecular parameters. M. Batus, M.J. Fidler, S. Basu, J.S. Coon, L. Buckingham, K. Kaiser-Walters, S.E.
McCormack and P. Bonomi. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings
(Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 22080.
33. Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer
(NSCLC) patients treated with gefitinib. M. J. Fidler, S. Basu, L. Buckingham, K. Kaiser, S. E. McCormack,
J. S. Coon, IV and P. D. Bonomi. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings
(Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 8036.
34. Tumor suppressor gene CpG site methylation and outcome in surgically treated stage I-II non-small cell
lung cancer patients. L. Buckingham, L. P. Faber, A. W. Kim, K. Kaiser, C. Barger, S. Basu, M. J. Liptay,
P. D. Bonomi and J. S. Coon. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings
(Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 11035.
35. The Prognostic importance of gene copy number in resectable non-small cell lung cancer (NSCLC) stages
1b-2b. Larry Morrison, L Faber, Kelly Walters, Mike Liptay, Teresa Ruffalo, Omid Rouhi, Shannon
McCormack, Diana Escazega, Ekaterina Pestova, Philip Bonomi, and John Coon. AACR Meeting
Abstracts, Apr 2008; 2008: 5550.
36. Gene promoter methylation and outcome in surgically treated stage I-II non-small cell lung cancer patients.
Lela Buckingham, L Faber, Anthony Kim, Kelly Kaiser, Sanjib Basu, Michael Liptay, Philip Bonomi, and
John Coon. AACR Meeting Abstracts, Apr 2008; 2008: 5549.
37. A Serum proteomic analysis of lung squamous cell carcinoma: Jeffrey A Borgia, casey frakenberger,
Sanjib basu, Kelly a kaiser, Shannon e mccormack, L.P. Faber, Michael J Liptay, Philip Bonomi, John S.
Coon. Journal of Thoracic Oncology. August 2007, Volume 2, Issue 8, ppS511-S512. August 2007.
(Proceedings from the 11th World Conference on Lung Cancer. September 2-6, 2007)
38. Discovery of serum biomarkers for squamous cell lung carcinoma using novel proteomic methods. Jeffrey
Borgia, Casey Frankenberger, L. Faber, Kelly Kaiser, Shannon McCormack, Philip Bonomi, and John
Coon. AACR Meeting Abstracts, Apr 2007; 2007: 610.
39. N-cadherin, a potential novel therapeutic target in small cell lung cancer. M. Batus, K. A. Kaiser, J. S.
Coon, S. Ahmed, A. Patel, E. F. Avery, M. A. Kemper, M. Kassar and P. D. Bonomi Journal of Clinical
Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20
Supplement), 2007: 18134.
40. Serum biomarker discovery for ovarian serous carcinoma using novel proteomic methods J. A. Borgia, C.
Frankenberger, K. Kaiser, S. E. McCormack, L. Usha, J. Rotmensch and J. S. Coon Journal of Clinical
Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20
Supplement), 2007: 16058
41. Clinical and molecular characteristics of advanced non-small cell lung cancer (NSCLC) patients (pts) with
rapid progressive disease (RPD) on gefitinib therapy (G). M. J. Fidler, L. Buckingham, M. Gale, J. Coon,
A. Mauer, V. Villaflor, K. A. Kaiser, S. McCormack, L. Morrison, P. Bonomi. Journal of Clinical
Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:
7592.
42. Clinical and molecular characteristics of advanced non-small cell lung cancer (NSCLC) patients (pts) with
rapid progressive disease (RPD) on gefitinib therapy (G): P3-067. Fidler, Mary J.; Buckingham, Lela; Gale,
Meryl; Iv, John Coon; Mauer, Ann; Villaflor, Victoria; Kaiser, Kelly; McCormack, Shannon; Bonomi,
Phillip. Journal of Thoracic Oncology. 2(8):S706-S707, August 2007.
43. The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with
Gefitinib. Buckingham, Lela E.; Coon, John S.; Morrison, Larry E.; Jacobson, Kristine K. B.; Jewell, Susan
S.; Kaiser, Kelly A.; Mauer, Ann M.; Muzzafar, Tariq; Polowy, Clayton; Basu, Sanjib; Gale, Meryl;
Villaflor, Victoria M.; Bonomi, Philip. Journal of Thoracic Oncology. 2(5):414-422, May 2007.
44. EGFR mutations (muts), IHC and FISH status, and chromosome 7 gene copy number combined with pAkt
expression as potential predictors of survival in non-small cell lung cancer (NSCLC) patients (pts) treated
with gefitinib (GEF). V. M. Villaflor, L. Buckingham, M. Gale, J. Coon, A. M. Mauer, T. Muzzafar, K.
Kaiser, M. Shannon, L. Morrison, P. Bonomi. Journal of Clinical Oncology, 2006 ASCO Annual Meeting
Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7182.
45. Associations between chromosome 7 aneusomy and EGFR copy number with survival and response to
gefitinib in NSCLC. L. E. Morrison, S. S. Jewell, K. K. Jacobson, K. Kaiser, M. Gale, T. Muzzafar, A. M.
Mauer, V. M. Villaflor, P. Bonomi, J. S. Coon. Journal of Clinical Oncology, 2006 ASCO Annual Meeting
Proceedings Part I. Vol 24, No. 18S (June 20 Supplement) 2006: 7171.
46. Biomarker discovery in endometrial carcinoma using novel proteomic methods. J. A. Borgia, C.
Frankenberger, S. E. McCormack, K. A. Kaiser, L. Usha, J. Rotmensch and J. S. Coon Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20
Supplement), 2006: 5034.
47. EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung
cancer (NSCLC) patients (pts). V. M. Villaflor, L. Buckingham, M. Gale, J. Coon, A. M. Mauer, T.
Muzzafar, K. Kaiser, T. W. Zusag, L. P. Faber, P. Bonomi. Journal of Clinical Oncology, 2005 ASCO
Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7077.
48. Local response to anthracycline-based therapy and patient outcome in locally advanced breast cancer are
linked to TOP2A, and p16 is a strong predictor of systemic outcome. John S. Coon, Elizabeth Marcus,
Shalina Gupta-Burt, Kris K. Jacobson, Vivian Renta, Ivanka Lukic, Kelly Kaiser, and Larry E. Morrison.
AACR Meeting Abstracts, Mar 2004; 2004: 266.
49. Genomic microarray analysis may predict outcome in NSCLC. Coon JS, Rao R, Ruffalo T, Kaiser K,
Polowy C, Pestova E, Marble T, Lukic I, Buckingham L, Wilber K, Bonomi P, King W. Lung Cancer,
Vol. 41, Supplement 2: 52, 2003.
50. Microarray analysis of genomic changes in lung carcinomas. Coon J, Ruffalo T, Kaiser K, Pestova E,
Marble T, Lucas M, Lukic I, Buckingham L, Wilber K, King W.. Proc. Amer. Assoc. Cancer Res, 44: 737738, 2003.